Dosage and usage of Glecaprevir/pibrentasvir tablets

Glecaprevir/pibrentasvir tablets (Glecaprevir/pibrentasvir) are used to treat patients with hepatitis C virus (HCV). Before starting treatment, necessary testing must be performed to ensure patient safety and effectiveness. Specific steps include assessing patients for current or previous HBV infection by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc).

Forpatients 3 years of age and older, the duration of treatment depends on the patient's specific condition. For untreated patients with HCV genotypes 1, 2, 3, 4, 5, or 6 who do not have cirrhosis or compensated cirrhosis (Child Pugh A), the usual recommended treatment duration is 8 weeks. For treatment-experienced patients, the recommended treatment duration may be 8, 12, or 16 weeks based on their prior treatment history, HCV genotype, and the presence of compensated cirrhosis.

In terms of dosage, glecaprevir and pibrentasvir tablets are a fixed compound drug. Each tablet contains glecaprevir100 mg and pibrentasvir 40 mg. The recommended dose for adults is 3 tablets once daily, taken with food, for a total dose of 300 mg of glecaprevir and 120 mg of pibrentasvir. For pediatric patients aged 3 to 12 years old and weighing less than 45 kg, it is recommended to use oral granules, each containing 50 mg of glecaprevir and 20 mg of pibrentasvir. For pediatric patients aged 12 years and above or weighing at least 45 kg, it is recommended to use glecaprevir and pibrentasvir tablets, 3 tablets once a day, with food.

In addition, for patients who have received a liver or kidney transplant, it is recommended to use glecaprevir and pibrentasvir tablets for 12 weeks of treatment. For patients with genotype 1 infection who have not been previously treated with NS3/4A protease inhibitors and have experience with NS5A inhibitors, or for patients with genotype 3 infection who have experience with PRS treatment, the recommended treatment duration is 16 weeks.

In short, when using glecaprevir and pibrentasvir tablets, doctors need to develop a personalized treatment plan based on the patient's specific conditions and strictly follow the recommended dosage and usage to ensure optimal treatment effects.

Reference materials:https://www.mavyret.com/